Study of Oxaliplatin and Sorafenib Combination to Treat Gastric Cancer Relapsed After a Cisplatin Based Treatment

NCT01262482 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (Relapsed After a Cisplatin Based Treatment)

Interventions

DRUG: Oxaliplatin
DRUG: Sorafenib

Sponsor

Grupo Espanol Multidisciplinario del Cancer Digestivo